While many started to learn about the Skulpt Aim within the past year and a half, Skulpt is actually a 6 year old company with a rich history. The proprietary technology behind the Skulpt Aim was used in the medical space for years. It has been validated through dozens on clinical trials, used in top US research hospitals, and has even been used by NASA to track the weightlessness of mice in space.
Skulpt, previously known as Convergence Medical Devices, was founded in 2009, but the research behind it started about 16 years ago. The idea of the Skulpt Aim began in 2013 to introduce Electrical Impedance Myography (EIM) to consumers and further develop its potential in the fitness space.
April 1999: Seward Rutkove, Skulpt co-founder and Neurology professor at Harvard Medical School, first conceives of Electrical Impedance Myography as a new tool to evaluate neuromuscular disease, out of frustration that there was no good way to measure the muscle health of his patients.
1999-2003: Data was collected on healthy subjects and neuromuscular disease patients, including muscle disease and ALS patients.
2003: National Institute of Health (NIH) provided funding to pursue further development and testing of EIM in a large group of healthy and neuromuscular disease patients.
2005: Studies in rats and mice were initiated to better understand mechanisms of impedance change in disease states.
2007: Collaboration with Joel Dawson, PhD at MIT’s department of electrical engineering and computer science was initiated to develop first handheld EIM device.
July 8, 2009: Jose Bohorquez, PhD, and Seward Rutkove, MD founded Convergence Medical Devices (CMD), to commercialize impedance devices for easy clinical use in patients with nerve and muscle diseases. CMD becomes involved in multiple clinical studies.
February 2011: Seward Rutkove wins $1,000,000 prize from the non-profit organization Prize4Life for his work in developing EIM and its use as a biomarker in ALS.
June 2013: Convergence Medical Devices is renamed to Skulpt, Inc to emphasize its new focus on fitness, measuring muscle quality and fat %. The work in neuromuscular disease still continues.
Aim is the world’s first consumer device to measure the muscle quality of individual muscles, and accurately measure body fat percentage.